Open AccessHypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact
Author(s) -
Trond Espen Detlie,
Jonas Christoffer Lindstrøm,
Marte Eide Jahnsen,
Elisabeth Finnes,
Heinz Zoller,
Bjørn Moum,
Jørgen Jahnsen
Publication year - 2021
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v27.i17.2039
Subject(s) - hypophosphatemia , medicine , gastroenterology , incidence (geometry) , inflammatory bowel disease , adverse effect , prospective cohort study , iron deficiency , surgery , anemia , disease , physics , optics
High-dose intravenous iron is an effective treatment option for iron deficiency (ID) or ID anaemia (IDA) in inflammatory bowel disease (IBD). However, treatment with ferric carboxymaltose (FCM) has been associated with the development of hypophosphatemia.